BioPlus Co Ltd
KOSDAQ:099430
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioPlus Co Ltd
Other Equity
BioPlus Co Ltd
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Other Equity
₩641.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Suheung Co Ltd
KRX:008490
|
Other Equity
₩10.4B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
8%
|
|
|
SD Biosensor Inc
KRX:137310
|
Other Equity
₩273.8B
|
CAGR 3-Years
143%
|
CAGR 5-Years
667%
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Inc
KOSDAQ:028300
|
Other Equity
-₩161.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-27%
|
|
|
O
|
Optus Pharmaceutical Co Ltd
KOSDAQ:131030
|
Other Equity
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Other Equity
₩607.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
See Also
What is BioPlus Co Ltd's Other Equity?
Other Equity
641.9m
KRW
Based on the financial report for Dec 31, 2024, BioPlus Co Ltd's Other Equity amounts to 641.9m KRW.
What is BioPlus Co Ltd's Other Equity growth rate?
Other Equity CAGR 5Y
-6%
Over the last year, the Other Equity growth was -68%. The average annual Other Equity growth rates for BioPlus Co Ltd have been 2% over the past three years , -6% over the past five years .
